Target Trial Emulation: Glucagon-Like Peptide 1 Receptor Agonist, Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors for Kidney Outcome Prevention

Key Result

GLP-1 receptor agonists and SGLT2 inhibitors as add-on diabetes treatments were associated with lower risks of kidney events and death, highlighting their value in primary prevention.

Key Points

• The research aims to assess the effectiveness of GLP1RA and SGLT2i in preventing kidney-related outcomes among diabetic individuals.
• Emulation of target trials to analyze treatment impacts on kidney outcomes.
• Focused on glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) as add-on therapies.
• Included analyses across different subgroups, particularly older adults.
• GLP1RA and SGLT2i significantly reduced composite kidney outcomes and mortality.
• The benefits were consistent across various subgroups, reinforcing primary prevention strategies.
• Indications of lower rates of kidney events and death support the use of these treatments.